We have upgraded our rating to Outperform (from Neutral) with a new target price of € 59 based on strong growth dynamics at the biopharma business and more favourable momentum with improving profitability at Helios Germany. We have raised our EPS estimates by 3% to 7%. Valuation multiples appear highly attractive given the growth trend on the bottom line.
    
            Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.